Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | IDO1 | P14902 | 6/20 | 0.47 |
| ▸ | TDO2 | P48775 | 5/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 5/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31642655 | 1.00 | NOS1 (0.50) | NOS1AXLIDO1TDO2PTPN6 | |
| SCHEMBL17875686 | 0.79 | TDO2 (0.66) | NOS1AXLIDO1TDO2PTPN6 | |
| SCHEMBL2144932 | 0.78 | IDO1 (0.47) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL26075080 | 0.76 | NOS1 (0.41) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL30621711 | 0.76 | NOS1 (0.41) | NOS1AXLIDO1TDO2METAP2 | |
| SCHEMBL31217417 | 0.76 | IDO1 (0.56) | NOS1AXLIDO1TDO2PTPN6 | |
| SCHEMBL1415060 | 0.76 | NOS1 (0.50) | NOS1AXLIDO1TDO2PTPN6 | |
| SCHEMBL29793841 | 0.76 | IDO1 (0.59) | NOS1AXLIDO1TDO2PTPN6 | |
| SCHEMBL2007139 | 0.76 | IDO1 (0.59) | NOS1AXLIDO1TDO2PTPN6 | |
| SCHEMBL29981288 | 0.76 | METAP2 (0.53) | NOS1AXLIDO1TDO2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594305-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968359-A | TEAD inhibitors and methods of use thereof | 英矽智能科技知识产权有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-12103915-B2 | TEAD inhibitors and methods of uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2024-10-01 | — | — | US | disclosed |
| US-20240166608-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-23 | — | — | US | disclosed |
| WO-2024067773-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-04-04 | — | — | WO | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12103915-B2 | TEAD inhibitors and methods of uses thereof | TEAD2, TEAD3, TEAD4 | NOS1 3823/4885AXL 4529/4885IDO1 3596/4885 |
| US-20240166608-A1 | TEAD INHIBITORS AND METHODS OF USES THEREOF | TEAD2, TEAD3, TEAD4 | NOS1 3823/4885AXL 4529/4885IDO1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.